Tamara K. Moyo, MD
Institution
Atrium health
Physician Status
accepting new patients
Primary Disease Area of Focus
Chronic Lymphocytic Leukemia (CLL)
patient
Adriana K Malone, MD
Institution
Icahn School of Medicine at Mount Sinai
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Leo Luznik, MD
Institution
Johns Hopkins University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Sydney X. Lu, MD
Institution
Stanford University School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndromes (MDS)
Thomas P. Loughran Jr, MD
Institution
UVA Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Bradley H. Lewis, MD
Institution
Permanente Medical Group Inc
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: Phase 2 ESCALATE trial
Original Publication Date
Article Source
External Web Content
Key Points Eltrombopag combined with IST demonstrated a trend towards a favorable ORR in pediatric patients with r/r SAA. The PK profile for eltrombopag was similar to that observed in patients with ITP, and no unexpected safety signals were observed in children Severe aplastic…
Donor regulatory T-cell therapy to prevent graft-versus-host disease
Original Publication Date
Article Source
External Web Content
Key Points Treg-engineered donor graft prevents acute and chronic GVHD. Patients treated with Treg-engineered graft who develop GVHD respond to primary corticosteroid therapy at a high rate. Abstract Allogeneic hematopoietic cell transplantation is a curative therapy limited by…
Taking Charge of My Care and Advocacy Following a Cancer Diagnosis
Original Publication Date
Article Source
External Web Content
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis. Almost every cancer survivor will agree that we end up going to too many doctors. A friend of mine with both cancer and diabetes…
Prognostic Significance of Monocytic-like Phenotype in AML patients treated with Venetoclax and Azacytidine
Original Publication Date
Article Source
External Web Content
Key Points Flow cytometry enhances morphological analysis to detect AML blasts with monocytic differentiation (mono-blasts). A high mono-blasts/CD45+ proportion cells predicts poor response and reduced survival in newly diagnosed AML patients receiving Ven-Aza The prognostic…